Crescent Biopharma grants options with 14.24 strike
Crescent Biopharma disclosed options for 31,200 shares to two employees, with a 14.24 exercise price and a 10-year term, approved on September 24, 2026.
Crescent Biopharma, Inc. disclosed a grant of options covering 31,200 shares for two employees, approved on September 24, 2026.
The company’s lead program is a PD-1 x VEGF bispecific antibody.
The options carry an exercise price of 14.24 and an options term of 10.
Source: GlobeNewswire, 25 Sept 2026
Sysco Corporation closed a C$1.5 billion offering and estimated the issuers would receive C$1.49 billion.
traderpublic Newsroom
Veracyte will present eight studies at ASTRO 2026 in Boston from September 26–30, 2026.
traderpublic Newsroom
Ocugen said OCU400 won orphan drug, RMAT and priority designations and provisional approval, with a Phase 3 readout due in 1Q 2027.
traderpublic Newsroom
